Lanreotide

Drug Profile

Lanreotide

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Growth hormone releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase II Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Coronary artery restenosis; Diabetic retinopathy; Gastrointestinal cancer; Graves ophthalmopathy; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 18 Sep 2017 Registered for Malignant carcinoid syndrome in USA (SC)
  • 08 Sep 2017 Efficacy and adverse events data from the phase III open-label extension study of the CLARINET trial in Neuroendocrine tumour presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 03 Jul 2017 Launched for Neuroendocrine tumours in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top